

**Table S1: Overall Survival and Cause Specific Survival Percentages**

	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Overall Survival</b>	<b>72.9% (72.0% - 73.7%)</b>	<b>54.7% (53.7% - 55.7%)</b>
<b>Cause-Specific Survival</b>	<b>74.2% (73.3% - 75.2%)</b>	<b>60.0% (59.0% - 61.1%)</b>

**Table S2: 1-year and 5-year Survival Percentages by Gender**

<b><u>Sex</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Females</b>	<b>76.9% (75.7% - 78.1%)</b>	<b>59.0% (57.6% - 60.5%)</b>
<b>Males</b>	<b>69.1% (67.9% - 70.4%)</b>	<b>50.7% (49.3% - 52.1%)</b>

**Table S3: 1-year and 5-year Survival Percentages by Race**

<b><u>Race</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>White</b>	<b>70.9% (69.8% - 72.0%)</b>	<b>52.6% (51.3% - 53.8%)</b>
<b>Black</b>	<b>77.6% (75.5% - 79.8%)</b>	<b>59.7% (57.1% - 62.4%)</b>
<b>Hispanic</b>	<b>74.7% (72.3% - 77.2%)</b>	<b>56.5% (52.6% - 59.5%)</b>
<b>Asian</b>	<b>74.8% (71.3% - 78.4%)</b>	<b>56.0% (51.9% - 60.4%)</b>

**Table S4: 1-year and 5-year Survival Percentages by Age**

<b><u>Age</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>&lt; 65 years old</b>	<b>81.7% (80.7% - 82.8%)</b>	<b>68.2% (66.9% - 69.5%)</b>
<b>≥ 65 years old</b>	<b>62.4% (61.0% - 63.8%)</b>	<b>38.9% (37.4% - 40.4%)</b>

**Table S5: 1-year and 5-year Survival Percentages by Tumor Stage**

<b><u>Tumor Stage</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Localized</b>	92.4% (91.5% - 93.4%)	79.9% (78.4% - 81.4%)
<b>Regional</b>	82.3% (80.8% - 83.8%)	63.2% (61.3% - 65.2%)
<b>Distant</b>	46.1% (44.5% - 47.8%)	24.0% (22.5% - 25.5%)

**Table S6: 1-year and 5-year Survival Percentages by Tumor Size**

<b><u>Tumor Size</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>&lt; 2 cm</b>	93.1% (92.1% - 94.2%)	79.8% (78.2% - 81.5%)
<b>2 cm – 4 cm</b>	81.4% (79.5% - 83.4%)	60.8% (58.5% - 63.3%)
<b>&gt; 4 cm</b>	50.3% (47.6% - 53.2%)	27.6% (25.2% - 30.2%)

**Table S7: 1-year and 5-year Survival Percentages by Tumor Site**

<b><u>Tumor Site</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Esophagus</b>	31.1% (26.3% - 36.7%)	7.5% (4.9% - 11.6%)
<b>Small intestine</b>	88.7% (87.6% - 89.7%)	69.8% (68.2 – 71.4%)
<b>Ascending Colon</b>	42.5% (38.2% - 47.3%)	24.2% (20.5% - 28.6%)
<b>Transverse Colon</b>	38.8% (31.6% - 47.7%)	13.6% (8.9% - 20.8%)
<b>Descending Colon</b>	28.6% (19.7% - 41.7%)	23.7% (15.4% - 36.5%)
<b>Sigmoid Colon</b>	52.3% (46.4% - 59.0%)	39.9% (34.0% - 46.7%)

<b>Rectum</b>	79.6% (77.8 – 81.5%)	65.5% (63.3% - 67.8%)
<b>Appendix</b>	93.7% (91.8% - 95.5%)	86.5% (83.8% - 89.4%)
<b>Stomach</b>	65.5% (63.2% – 67.9%)	43.5% (40.7% - 46.0%)

**Table S8: 1-year and 5-year Survival Percentages by Regional Lymph Node Status**

<b><u>Nodal Status</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Negative</b>	87.5% (85.5% - 89.5%)	65.7% (62.7% - 68.8%)
<b>Positive</b>	76.3% (74.9% - 77.8%)	57.2% (55.4% - 58.9%)

**Table S9: 1-year and 5-year Survival Percentages by Treatment Modality**

<b><u>Treatment</u></b>	<b><u>1-year Survival (95% C.I)</u></b>	<b><u>5-year Survival (95% C.I)</u></b>
<b>Chemotherapy only</b>	34.9% (32.3% - 37.8%)	8.0% (6.4% - 10.0%)
<b>Surgery only</b>	87.3% (86.5% - 88.2%)	73.2% (72.0% - 74.4%)
<b>Chemotherapy and Surgery</b>	65.3% (62.1% - 68.7%)	33.6% (30.3% - 37.2%)
<b>None</b>	56.1% (54.0% - 58.3%)	39.4% (37.1% - 41.7%)

**Figure S1: Survival Analysis of GINEC cases based on Housing location (A) and Median Annual Household Income (B)**

